Edmonton, Alberta, February 6, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Ms. Amanda Stadel, Investor Relations Manager, will present at a session hosted by BioAlberta, Alberta’s life science industry association, as part of the 7th Annual BioPartnering North America Conference in Vancouver.
This workshop will profile activities within Alberta’s world-class health and biotechnology institutes as well as showcase companies that are active in the region.
TITLE: “Need + Innovation = Opportunity...Alberta, Canada”
WHEN: Monday February 9th at 4:30pm (Pacific Time)
WHERE: Westin Bayshore Resort, Vancouver
About BioPartnering North America
BioPartnering North America brings together decision-makers from leading biotechnology, pharmaceutical and investment companies and features company presentations, partnering meetings and expert panels and workshops. For more information visit http://www.techvision.com/bpn/
About BioAlberta
BioAlberta is a private, not-for-profit industry association, representing Alberta’s growing bioindustry. For more information visit http://www.bioalberta.com/index.asp
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com
This press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
